The gap between the first and booster doses of Pfizer (NYSE: PFE) and BioNTech‘s (NASDAQ: BNTX) coronavirus vaccine has been widened substantially in the U.K. — and Pfizer is not pleased about it.
The U.K.’s joint committee on vaccination and immunization, an advisory body that advises government healthcare agencies, approved new dosing guidelines for both Pfizer/BioNTech’s BNT162b2 and the just-approved AZD1222 from AstraZeneca and the University of Oxford. The new guidelines state that both vaccines’ two requisite shots can be administered as much as three months apart.
The key aim of the new recommendation appears to be to get as many people inoculated as possible with the initial shot. Research indicates that partial protection against the coronavirus can start as soon as 12 days after the first jab.